Rituximab: A Popular But Problematic Biosimilar
Roche/ Biogen Idec’s $7 billion oncology and rheumatoid arthritis monoclonal antibody rituximab has been a far more popular target than infliximab for biosimilar developers.
You may also be interested in...
BD Diagnostics has gained emergency use authorization (EUA) for a handheld rapid COVID-19 antigen test that could play a pivotal role in fighting an ongoing surge of coronavirus outbreaks. See what US FDA commissioner Stephen Hahn said about it here.
US government to own doses of Regeneron's investigational cocktail antibody REGN-COV2 manufactured under a $450m contract and 100 million doses of Novavax's investigational vaccine under a $1.6bn agreement.
FDA approval for Perrigo's ANDA for two loperamide products listed as tablets follows CBE label changes Johnson & Johnson and BionPharma made for their branded OTCs containing the ingredient in 2019.